
Veana is currently trialing their oral pill that is designed to target breast cancer. The pill is designed to destabilize the mitochondria of the cancer cell, which allows cancer cells to be killed selectively. Preliminary trial data look promising regarding clinical results.

Investment Details
Funding Round
Seed
Milestones
Funded in 2023

About the Founder
Patricia Beckman
Patricia Beckman's career spans over 30 years in the biopharma industry, spanning research, operations, venture capital, and law. She founded Veana Theraputics, a biotechnology company trialing an oral pill designed to destabilize cancer cells. Beckman founded the Life Science Washington Institute and serves as the Executive Director of the Oregon Translation Research and Development Institute.
Real Investors. Real Outcomes.
Start Your Investing Journey with Portfolia
Our live overview sessions are the best way to experience how Portfolia is transforming venture capital and why the experience is unmatched.
- MEET OUR PARTNERS
- LEARN HOW OUR FUNDS WORK
- SEE THE COMPANIES WE'RE BACKING.


